With the great opportunities that Personalized Medicine offers comes the need of novel biomarkers for clinical application. The human proteome is greatly affected during disease and holds information from both physiological and pathological processes. The proteome is therefore a rich resource of novel potential protein with great clinical potential. Mass spectrometry is an important proteomics discovery tool that can quantitatively measure thousands of proteins in a sample. To move novel potential protein markers towards clinical use they need to be verified in independent datasets with technology that can easily be translated into clinical use. Mass spectrometry (MS) has also been used in clinical laboratories for decades to measure small molecules and is now increasingly being used for targeted protein analysis in an assay setting as a MS-ELISA. With this seamless transition of protein analysis from discovery to verification to clinical assays this protein analysis approach holds great promise to actually transfer novel protein biomarkers from discovery into clinical practice. My research focus is specializing in moving potential protein markers towards clinical use through this process developing MS-assays. More specifically we also combine mass MS with recombinant antibody technology to combine the sensitivity of antibodies to capture small amounts of target molecules with the targeted readout of the MS in a platform we have developed called AFFIRM.